CDK7 radiopharmaceutical development for improved diagnostics of glioblastoma with Positron Emission Tomography (PET)

Clinical research data has proven that PET scanning is superior to conventional imaging in the diagnosis and management of various types of cancers. PET provides insights into the biology of brain tumors that extend beyond MRI and other available techniques. This includes its use in differential diagnosis, non-invasive grading, delineating the extent of tumoral tissue for planning surgery and radiotherapy, as well as aiding in post-treatment monitoring and prognostics. The most applied radiotracer in PET cancer diagnostics, [ 18F]FDG, represents approximately 80% of all clinical PET applications and, although its clearly effective in detecting pathological changes in a wide range of disease conditions, it is not specific for glioblastoma. Thus, to fully utilise the benefits of PET imaging for brain tumor, new radiotracers are needed. This project aims to explore the potential for a commercial development of a new lead radiotracer for brain tumor imaging.

We have established network with industry partners to advise on required documentations for commercialising the tracer and confirmed lisencing as a viable commercialisation route with interested parties. IPR strategy is set and patent filing has been postponed until the technology has matured more.